---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-23-000005"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2023-02-03T23:59:59+00:00"
generated_at: "2026-06-20T01:31:18.056040+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q4 revenue down 31% to $3.41B, core up 14%; GAAP EPS $10.50

## Summary
- Q4 total revenues $3.41B (-31% YoY); ex-REGEN-COV/Ronapreve up 14% to $3.02B.
- GAAP diluted EPS $10.50 (Q4) and $38.22 (FY); non-GAAP $12.56 (Q4) and $44.98 (FY).
- EYLEA U.S. net sales $1.50B Q4 (-3%), FY $6.26B (+8%); Dupixent global net sales $2.45B Q4 (+38%), FY $8.68B (+40%).
- Aflibercept 8 mg BLA submitted for wet AMD/DME in Dec 2022; FDA approved Libtayo+chemo for NSCLC; EC approved Dupixent for prurigo nodularis and EoE.
- New $3.0B share repurchase program authorized Jan 2023; FY2023 guidance: non-GAAP R&D $3.725-3.925B, non-GAAP SG&A $2.130-2.280B.

## SEC filing metadata
- accession: 0001804220-23-000005
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2023-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422023000005/0001804220-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422023000005/regn-20230203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-23-000005
- JSON: https://secwatch.observer/filing/0001804220-23-000005.json
- Plain text: https://secwatch.observer/filing/0001804220-23-000005.txt

## Key facts
- Earnings Releases
  REGENERON PHARMACEUTICALS, INC. reported Fourth Quarter 2022 results: revenue $3,414 million, net income $1,197 million, EPS $10.50.
  - Period: Fourth Quarter 2022
  - Revenue: $3,414 million
  - Net income: $1,197 million
  - EPS: $10.50
  - Result: reported results
  source text: 99.1 Document Exhibit 99.1 Press Release Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results • Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV ® and Ronapreve TM (a)(b) , revenues increased 14% • Full year 2022 revenues decreased 24% to $12.17 billion versus full year
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000180422023000005/0001804220-23-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.